ImmunoGen Inc (IMGN)

[skitahoe]

https://www.asbestos.com/news/2016/10/05/david-sugarbaker-mesothelioma-clinical-trial-home-run/

Not sure if anyone here's seen this, but today was the first time I did. The Bayer drug they're citing is the one that recently completed patient enrollment and which could be approved out of Phase II. Now the question become, with really excellent result which seem to be the case, could the drug be approved this year.

I'm certainly not saying it can, or will be, but I believe that if Trump does appoint someone to head the FDA who pushes for faster approval and lower trial costs, I believe it's very possibly.

I don't know precisely how much IMGN will see in milestones by the time the drug is approved, but suspect it could be somewhere in the $25 million range as I believe the overall milestones exceed $200 million. No doubt, many of the milestones are tied to annual sales levels, but we might all be surprised to see this, and routine royalty payments far sooner than anticipated.

Gary